CD8A and cancer: Additionally, despite superior tumor rejection, a higher expression of the of the inhibitory receptor NKG2A, which is frequently elevated in patients with HPV16+ cancer [37], was observed on E7-specific CD8+ TIL taken from mice treated with combination therapy, indicating that triplet combination therapy with anti-NKG2A immune checkpoint blockade [37] could further boost the anti-tumor efficacy of combined E7 RNA-LPX/LRT in TC-1 tumor-bearing mice and patients with HPV16+ cancer.